ArticleJournal of materials science. Materials in medicine2025
Nanocomposite hydrogel incorporating Arnica montana extract, propolis-loaded chitosan nanoparticles, and menstrual blood-derived mesenchymal stem cells for allergic rhinitis therapy.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baicalin: A comprehensive review of its molecular mechanisms and pharmacological activities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Allergic rhinitis (AR) is a common inflammatory condition requiring innovative therapeutic approaches. This study introduces a nanocomposite hydrogel system combining Arnica montana extract and propolis-loaded chitosan nanoparticles (AMEPROCNPs) with menstrual blood-derived mesenchymal stem cells (MenSCs), designed for sustained delivery and enhanced mucosal healing. The system demonstrated biocompatibility, effective drug release, and strong mucoadhesion. In vitro studies showed marked reductions in pro-inflammatory cytokines, including IL-6, IL-1β, and TNF-α, alongside significant cytoprotection against oxidative stress. In vivo, the optimized formulation (HYDROMenSC-CNP-8) substantially alleviated AR symptoms and significantly downregulated key Th2-associated cytokines (IL-4, IL-5, IL-13) and TNF-α, while upregulating IFN-γ levels, comparable to Fluticasone Propionate. These results suggest that the AMEPROCNPs-loaded MenSC-collagen hydrogel represents a promising, safe, and effective alternative to current AR therapies. Furthermore, this system holds potential for broader application in treating other inflammatory and allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.